Images: Related links to external sites (from Bing)
Ontology:
Flavoxate
(C0016225)
Definition (NCI)
|
A synthetic parasympatholytic with antimuscarinic, muscle relaxant and urinary antispasmodic properties. Flavoxate binds and inhibits muscarinic receptors, thereby suppressing the micturition reflex and increases urinary bladder capacity by modifying the micturition center in the brain stem. In addition, this agent has been found to inhibit cyclic AMP formation in striatal membranes of the brain through stimulation of pertussis toxin-sensitive G protein-coupled receptors which in turn suppress isovolumetric urinary bladder contraction.
|
Definition (MSH)
|
A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist.
|
Concepts |
Pharmacologic Substance
(T121)
, Organic Chemical
(T109)
|
MSH |
D005422
|
SnomedCT |
372768002, 53641000 |
English |
Flavoxate, 4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinyl)ethyl ester, Flavoxate [Chemical/Ingredient], flavoxATE, flavoxate, FLAVOXATE, Flavoxate (product), Flavoxate (substance) |
Swedish |
Flavoxat
|
Czech |
flavoxát
|
Finnish |
Flavoksaatti
|
Russian |
FLAVOKSAT, ФЛАВОКСАТ |
Polish |
Flawoksat
|
Japanese |
塩酸フラボキサート, フラボキサート |
Spanish |
flavoxato (producto), flavoxato (sustancia), flavoxato, Flavoxato |
French |
Flavoxate
|
German |
Flavoxat
|
Italian |
Flavossato
|
Portuguese |
Flavoxato
|
Ontology:
Urispas
(C0042049)
Concepts |
Pharmacologic Substance
(T121)
, Organic Chemical
(T109)
|
MSH |
D005422
|
English |
urispas, Urispas, Byk Brand of Flavoxate Hydrochloride, Cahill May Roberts Brand of Flavoxate Hydrochloride, Negma Brand of Flavoxate Hydrochloride, Ortho Brand of Flavoxate Hydrochloride, Shire Brand of Flavoxate Hydrochloride |
Ontology:
oxybutynin
(C0069805)
Definition (NCI)
|
A tertiary amine possessing antimuscarinic and antispasmodic properties. Oxybutynin blocks muscarinic receptors in smooth muscle, hence inhibiting acetylcholine binding and subsequent reduction of involuntary muscle contractions. Oxybutynin is used to reduce bladder contractions by relaxing bladder smooth muscle.
|
Concepts |
Pharmacologic Substance
(T121)
, Organic Chemical
(T109)
|
MSH |
C005419
|
SnomedCT |
35768004, 372717000 |
LNC |
LP18095-7, MTHU003379 |
English |
4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate, 4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate, oxybutynin, OXYBUTYNIN @ @ UNIDENTIFIED, OXYBUTYNIN UNIDENTIFIED, Benzeneacetic Acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl Ester, 4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate, oxybutynin (medication), urological antispasmodics oxybutynin, OXYBUTYNIN, oxybutynin [Chemical/Ingredient], Oxybutynin, Oxybutynin (product), Oxybutynin (substance) |
Spanish |
oxibutinina (producto), oxibutinina (sustancia), oxibutinina |
Ontology:
Cystospaz
(C0305774)
Concepts |
Pharmacologic Substance
(T121)
, Organic Chemical
(T109)
|
English |
Cystospaz, cystospaz |
Ontology:
tolterodine
(C0388753)
Definition (NCI)
|
A benzhydryl compound and a muscarinic receptor antagonist possessing both antimuscarinic and antispasmodic properties. Both tolterodine and its active metabolite, 5-hydroxymethyltolterodine, competitively blocks muscarinic receptors, thereby inhibiting acetylcholine binding. This antagonistic action results in an increase in residual urine, reflecting an incomplete emptying of the bladder, and a decrease in detrusor pressure, indicating an antimuscarinic action on the lower urinary tract. The 5-hydroxymethyl metabolite appears to contribute significantly to the therapeutic effects.
|
Concepts |
Organic Chemical
(T109)
, Pharmacologic Substance
(T121)
|
MSH |
C099041
|
SnomedCT |
109113000, 372570008 |
LNC |
LP171645-7 |
English |
tolterodine, tolterodine [Chemical/Ingredient], TOLTERODINE, Tolterodine (product), Tolterodine (substance), Tolterodine |
Spanish |
tolterodina (producto), tolterodina (sustancia), tolterodina |
Ontology:
darifenacin
(C0529351)
Concepts |
Pharmacologic Substance
(T121)
, Organic Chemical
(T109)
|
MSH |
C101207
|
SnomedCT |
416385001, 416140008 |
English |
(S)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide, darifenacin, darifenacine, darifenacin (medication), DARIFENACIN, darifenacin [Chemical/Ingredient], darifenicin, Darifenacin (product), Darifenacin (substance), Darifenacin |
Spanish |
darifenacina (producto), darifenacina (sustancia), darifenacina |
Ontology:
Ditropan
(C0591395)
Concepts |
Pharmacologic Substance
(T121)
, Organic Chemical
(T109)
|
MSH |
C005419
|
English |
Cystrin, ditropan, Aventis brand of oxybutynin hydrochloride, Byk brand of oxybutynin hydrochloride, Dridase, Janssen brand of oxybutynin hydrochloride, Ortho brand of oxybutynin hydrochloride, Sanofi Synthelabo brand of oxybutynin hydrochloride, Allphar brand of oxybutynin hydrochloride, Ditropan |
Ontology:
Detrol
(C0719805)
Concepts |
Pharmacologic Substance
(T121)
, Organic Chemical
(T109)
|
MSH |
C099041
|
English |
Detrol, Pfizer brand of tolterodine tartrate, detrusitol, detrol, Detrusitol, Unidet |
Ontology:
ANTISPASMODICS,URINARY
(C0876271)
Concepts |
Pharmacologic Substance
(T121)
|
English |
ANTISPASMODICS,URINARY, [GU201] ANTISPASMODICS,URINARY, [GU200] ANTISPASMODICS,URINARY, antispasmodic urinary, urinary antispasmodics, Antispasmodics, Urinary |
Ontology:
Solifenacin
(C1099677)
Concepts |
Pharmacologic Substance
(T121)
, Organic Chemical
(T109)
|
MSH |
C441209
|
SnomedCT |
407031006, 407030007 |
English |
solifenacin, 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,1- azabicyclo(2.2.2)oct-3-yl ester, (R-(R*,S*))-, SOLIFENACIN, Solifenacin (product), Solifenacin (substance), Solifenacin |
Spanish |
solifenacina (producto), solifenacina (sustancia), solifenacina |
Ontology:
Enablex
(C1310721)
Concepts |
Organic Chemical
(T109)
, Pharmacologic Substance
(T121)
|
MSH |
C101207
|
English |
Enablex
|
Ontology:
VESICARE
(C1601338)
Concepts |
Organic Chemical
(T109)
, Pharmacologic Substance
(T121)
|
MSH |
C441209
|
English |
VESICARE, Vesicare, vesicare, Astellas Pharma US and GlaxoSmithKline brand of solifenacin succinate., VESIcare |
Ontology:
urinary tract antispasmodics
(C2064921)
Concepts |
Pharmacologic Substance
(T121)
|
English |
urological agents antispasmodics, urinary tract antispasmodics (medication), urinary tract antispasmodics |